Skip to content
10-Q

Quarterly Report

Bio-Rad Laboratories, Inc. BIO BIO-B

0000012208-25-000077

← back to feed
Filed
Oct 29, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q3 2025 · Sep 30, 2025 26.92M sh
Shares Diluted Q3 2025 · Sep 30, 2025 27.37M sh
Shares Diluted Q3 2025 · Sep 30, 2024 27.99M sh
Shares Diluted Q3 2025 · Sep 30, 2024 28.29M sh
Stock Repurchased Q3 2025 · Sep 30, 2025 $295.5M
Stock Repurchased restated Q3 2025 · Sep 30, 2024 $203.6M
Capex Q3 2025 · Sep 30, 2025 $111.8M
Capex restated Q3 2025 · Sep 30, 2024 $122.7M
Operating Cash Flow Q3 2025 · Sep 30, 2025 $367.3M
Operating Cash Flow restated Q3 2025 · Sep 30, 2024 $331M
Long Term Debt Q3 2025 · Sep 30, 2025 $1.2B
Long Term Debt Q3 2025 · Dec 31, 2024 $1.2B
Short Term Investments Q3 2025 · Sep 30, 2025 $1.02B
Short Term Investments Q3 2025 · Dec 31, 2024 $1.18B
Cash And Equivalents Q3 2025 · Sep 30, 2025 $395.8M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $488.1M
Cash And Equivalents restated Q3 2025 · Sep 30, 2024 $410.4M
Stockholders Equity Q3 2025 · Sep 30, 2025 $6.74B
Stockholders Equity Q3 2025 · Jun 30, 2025 $7.13B
Stockholders Equity Q3 2025 · Mar 31, 2025 $6.68B
Stockholders Equity Q3 2025 · Dec 31, 2024 $6.57B
Stockholders Equity restated Q3 2025 · Sep 30, 2024 $7.49B
Stockholders Equity restated Q3 2025 · Jun 30, 2024 $6.78B
Stockholders Equity restated Q3 2025 · Mar 31, 2024 $9.05B
Stockholders Equity restated Q3 2025 · Dec 31, 2023 $8.74B
Current Liabilities Q3 2025 · Sep 30, 2025 $522.3M
Current Liabilities Q3 2025 · Dec 31, 2024 $467.8M
Total Liabilities Q3 2025 · Sep 30, 2025 $2.96B
Total Liabilities Q3 2025 · Dec 31, 2024 $2.79B
Current Assets Q3 2025 · Sep 30, 2025 $2.84B
Current Assets Q3 2025 · Dec 31, 2024 $3.03B
Total Assets Q3 2025 · Sep 30, 2025 $9.7B
Total Assets Q3 2025 · Dec 31, 2024 $9.36B
Eps Diluted Q3 2025 · Sep 30, 2025 −$12.70
Eps Diluted Q3 2025 · Sep 30, 2025 $1.46
Eps Diluted Q3 2025 · Sep 30, 2024 $23.34
Eps Diluted Q3 2025 · Sep 30, 2024 −$39.89
Eps Basic Q3 2025 · Sep 30, 2025 −$12.70
Eps Basic Q3 2025 · Sep 30, 2025 $1.46
Eps Basic Q3 2025 · Sep 30, 2024 $23.37
Eps Basic Q3 2025 · Sep 30, 2024 −$39.89
Sga Expense Q3 2025 · Sep 30, 2025 $206.8M
Sga Expense Q3 2025 · Sep 30, 2025 $623.3M
Sga Expense restated Q3 2025 · Sep 30, 2024 $200.4M
Sga Expense restated Q3 2025 · Sep 30, 2024 $610M
Rd Expense Q3 2025 · Sep 30, 2025 $71.3M
Rd Expense Q3 2025 · Sep 30, 2025 $205.3M
Rd Expense restated Q3 2025 · Sep 30, 2024 $91M
Rd Expense restated Q3 2025 · Sep 30, 2024 $216.3M
Net Income Q3 2025 · Sep 30, 2025 −$341.9M
Net Income Q3 2025 · Sep 30, 2025 $39.9M
Net Income Q3 2025 · Jun 30, 2025 $317.8M
Net Income Q3 2025 · Mar 31, 2025 $64M
Net Income restated Q3 2025 · Sep 30, 2024 $653.2M
Net Income restated Q3 2025 · Sep 30, 2024 −$1.13B
Net Income restated Q3 2025 · Jun 30, 2024 −$2.17B
Net Income restated Q3 2025 · Mar 31, 2024 $383.9M
Operating Income Q3 2025 · Sep 30, 2025 $65.3M
Operating Income Q3 2025 · Sep 30, 2025 $166.1M
Operating Income restated Q3 2025 · Sep 30, 2024 $64.5M
Operating Income restated Q3 2025 · Sep 30, 2024 $210.7M
Gross Profit Q3 2025 · Sep 30, 2025 $343.4M
Gross Profit Q3 2025 · Sep 30, 2025 $994.7M
Gross Profit restated Q3 2025 · Sep 30, 2024 $355.9M
Gross Profit restated Q3 2025 · Sep 30, 2024 $1.04B
Cost Of Revenue Q3 2025 · Sep 30, 2025 $309.6M
Cost Of Revenue Q3 2025 · Sep 30, 2025 $895.3M
Cost Of Revenue restated Q3 2025 · Sep 30, 2024 $293.8M
Cost Of Revenue restated Q3 2025 · Sep 30, 2024 $862M
Revenue Q3 2025 · Sep 30, 2025 $653M
Revenue Q3 2025 · Sep 30, 2025 $1.89B
Revenue restated Q3 2025 · Sep 30, 2024 $649.7M
Revenue restated Q3 2025 · Sep 30, 2024 $1.9B